Valneva (NASDAQ:VALN) Shares Gap Up – Should You Buy?

Valneva SE (NASDAQ:VALN)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $6.71, but opened at $6.93. Valneva shares last traded at $6.78, with a volume of 1,473 shares.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Guggenheim lowered their target price on Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, March 24th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Valneva in a report on Monday.

Valneva Trading Up 1.0 %

The stock has a market cap of $550.54 million, a PE ratio of -52.12 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock has a fifty day moving average price of $6.67 and a 200 day moving average price of $5.59.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The firm had revenue of $56.48 million for the quarter, compared to analysts’ expectations of $55.64 million. Equities analysts expect that Valneva SE will post 0.13 EPS for the current year.

Institutional Trading of Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA purchased a new position in Valneva SE (NASDAQ:VALN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.